【正文】 – BACKGROUND 第一部分－背景知識 A primary mission of the Food and Drug Administration is to conduct prehensive regulatory coverage of all aspects of production and distribution of drugs and drug products to assure that such products meet the 501(a)(2)(B) requirements of the Act. FDA has developed two basic strategies: FDA的主要使命是對藥物和藥品生產(chǎn)和銷售的各個(gè)方面進(jìn)行全面的法規(guī)引導(dǎo)，以確保這些產(chǎn)品達(dá)到 法案 501(a)(2)(B)的要求。如果要把這些檢查項(xiàng)目擴(kuò)大成一個(gè) CGMP 檢查，則必須要根據(jù)本需遵守條例提出報(bào)告。 However, if information is encountered pertaining to inadequate postapproval reporting (Annual Reports,Supplements, Field Alert Reports, Adverse Drug Experience Reports, etc.) the information should be described in accordance with directions provided in those applicable pliance programs and under 但是，如果查出的信息與不恰當(dāng)?shù)氖潞笈鷾?zhǔn)報(bào)告（年終報(bào)表，補(bǔ)充， 現(xiàn)場警告報(bào)告 ，藥物不良反應(yīng)報(bào)告等）有關(guān)，則描述這些信息時(shí)要與有關(guān)的應(yīng)用上需要遵守的條款一致，并在工廠檢查報(bào)告（ EIR）內(nèi)有獨(dú)立的標(biāo)題進(jìn)行說明。s new drug approval decisions with respect to a firm, the District should report the information immediately according to current FACTS procedures. This includes filing OAI notifications and removing the notifications. 本綱要闡述了評估 CGMP遵守情況的方法指南。專門建立了一個(gè) 賬戶接收警告信。美國食品藥品管理局 GMP 檢查程序 指導(dǎo)手冊綱 要 公布日期： 2/1/2020 由 FDA 2438(7/92)提供 1 題目： 藥品生產(chǎn) 檢查 實(shí)施日期 2/1/2020 完成日期 繼續(xù) 數(shù)據(jù)報(bào)表 產(chǎn)品編號 產(chǎn)品 /分配編碼 所有人用藥 行業(yè)編號： 50， 5456， 59， 6066 國內(nèi) /國外檢查： 56002 56002A 無菌產(chǎn)品生產(chǎn) 56002B 重新包裝和重貼標(biāo)簽 56002C 放射性藥物 56002E 壓縮藥用氣體 56002F 原料藥 FIELD REPORTING REQUIREMENTS 現(xiàn)場報(bào)告要求 Forward a copy of each Establishment Inspection Report (EIR) for inspections classified as OAI due to CGMP deficiencies as part of any regulatory action remendation submitted to HFD300. For all inspections that result in the issuance of a Warning Letter, forward an electronic copy of each letter to the Division of Manufacturing and 美國食品藥品管理局 GMP 檢查程序 指導(dǎo)手冊綱 要 公布日期： 2/1/2020 由 FDA 2438(7/92)提供 2 Product Quality, Case Management and Guidance Branch (HFD325). An account has been established to receive copies of Warning Letters. The account address is CDERCGMPWL. 根據(jù) CGMP 缺陷提出的指定的正式行為（ OAI）進(jìn)行分類檢查后提出的 工廠檢查報(bào)告（ EIR） ，其復(fù)印件要轉(zhuǎn)發(fā)一份呈交到 HFD300，作為規(guī)范行為建議的一部分。對于檢查后發(fā)出警告信的情況，每封信的電子版都要轉(zhuǎn)發(fā)到生產(chǎn)和產(chǎn)品質(zhì)量部門，個(gè)案管理和指導(dǎo)部門（ HFD325）。該帳戶 地址是 CDERCGMPWL. This program provides guidance in evaluating pliance with CGMP requirements. As soon as the District bees aware of any significant inspectional, analytical, or other information developed under this program that may affect the agency39。檢查官根據(jù)該綱要進(jìn)行檢查，一旦發(fā)現(xiàn)該廠重大的檢查，分析或其它信息可能影響其新藥申請批準(zhǔn)時(shí)，應(yīng)立即根據(jù)當(dāng)前 FACTS程序提呈報(bào)告，包括整理 OAI通知和撤銷該通知。 美國食品藥品管理局 GMP 檢查程序 指導(dǎo)手冊綱 要 公布日期： 2/1/2020 由 FDA 2438(7/92)提供 3 separate captions in the EIR. Data system information about these inspectional activities should be reported using applicable separate PAC(s). Expansion of coverage under these programs into a CGMP inspection must be reported under this pliance program. 采用實(shí) 用的單獨(dú) PAC(s)，把這些檢查行動(dòng)以數(shù)據(jù)系統(tǒng)信息的方式進(jìn)行報(bào)告。 The Districts are requested to use this revised pliance program for all GMP inspections. 要求檢查官以該修訂的需遵守條例為準(zhǔn)，進(jìn)行 一切 GMP檢查。 FDA制定了兩個(gè)基本策略： 1) evaluating through factory inspections, including the collection and analysis of associated samples, the conditions and practices 美國食品藥品管理局 GMP 檢查程序 指導(dǎo)手冊綱 要 公布日期： 2/1/2020 由 FDA 2438(7/92)提供 4 under which drugs and drug products are manufactured, packed, tested and held, and 通過工廠 檢查進(jìn)行評估，包括收集和分析相關(guān)樣品，藥物和藥品生產(chǎn)、包裝、檢驗(yàn) 和質(zhì)量控制的條件和實(shí)踐，以及 2) monitoring the quality of drugs and drug products through surveillance activities such as sampling and analyzing products in distribution. 通過銷售時(shí)產(chǎn)品取樣和分析等監(jiān)督行為，對 藥物和藥品質(zhì)量進(jìn)行監(jiān)督。如果工廠的運(yùn)行處于控制狀態(tài)下，則達(dá)到本條例要求的產(chǎn)品生產(chǎn)和銷售能夠保證始終達(dá)到質(zhì)量合格標(biāo)準(zhǔn)。 The inspectional guidance in this program is structured to provide for efficient use of resources devoted to routine surveillance coverage, recognizing that indepth coverage of all systems and all processes is not feasible for all firms on a biennial basis. It also provides for followup pliance coverage as needed. FDA意識到每兩年對所有系統(tǒng)和過程全面檢查一次并不是對所有公司都切實(shí)可行，因此該綱要中的檢查指南旨在為日常監(jiān)督提供夠用的資源。 美國食品藥品管理局 GMP 檢查程序 指導(dǎo)手冊綱 要 公布日期： 2/1/2020 由 FDA 2438(7/92)提供 5 PART II IMPLEMENTATION 第二部分－實(shí) 施 OBJECTIVES 目標(biāo) The goal of this program39。 exposure to adulterated drug products. Under this program, inspections and investigations, sample collections and analyses, and regulatory or administrative followup are made: 實(shí)施 本程序 的目的是為了最大限度的減少消費(fèi)者買到 假冒偽劣 藥品的可能性， 要求遵照本 程序進(jìn) 行檢查和調(diào)查，樣品收集和分析以及進(jìn)一步 的 法規(guī)和管理： 1) to determine whether inspected firms are operating in pliance with applicable CGMP requirements, and if not, to provide the evidence for actions to prevent adulterated products from entering the market and as appropriate to remove adulterated products from the market, and to take action against persons responsible as appropriate。 提供 CGMP評估，用來有效判斷公司進(jìn)行新藥申 報(bào) 時(shí)工廠通過預(yù)批評審的可行性。 and, 對接受檢查的公司提出建議，幫助該公司提高遵守法規(guī)的力度；并， 4） to continue FDA39。 strategy 策略 A. Biennial Inspection of Manufacturing Sites (includes repackaging, contract labs, etc.) 對生產(chǎn)地點(diǎn)（包括重新包裝、簽約實(shí)驗(yàn)室 等）兩年檢查一次 Drugs and drug products are manufactured using many physical operations to bring together ponents and containers and closures into a product that is released for distribution. 在藥物和藥品生產(chǎn)過程中， 通過一系列 物理操作把各種成分 、容器以 及密封件加工成可以 放行 銷售 的產(chǎn)品。通過對這些系統(tǒng)的控制， 有助于 確保公司按要求生產(chǎn)出安全、均一、有效 的產(chǎn)品，并且符合預(yù)定的 質(zhì)量和純度 要求 。 降低假冒偽劣 產(chǎn)品進(jìn)入市場的危險(xiǎn)性； 2) increase munication between the industry and the Agency。 and, 對公司的新 生產(chǎn)操作及時(shí)進(jìn)行評估；并， 4) provide for regular feedback from the Agency to individual firms on the continuing status of the firm39。 This program applies to all drug manufacturing operations. 本綱要適用于所有藥品生產(chǎn)操作。如果按照外形分 類 進(jìn)行檢查 ，其 檢查 范圍可